参麦注射液辅助治疗重症急性胰腺炎的临床观察

Clinical Observation of Shenmai Injection as an Adjuvant Therapy for Severe Acute Pancreatitis

目的观察参麦注射液辅助治疗重症急性胰腺炎(SAP)的临床疗效。方法将SAP患者按照随机数字表法分为对照组44例(脱落2例,剔除2例,最终完成40例)与观察组45例(脱落1例,剔除3例,最终完成41例),对照组给予西医常规治疗措施,观察组在给予常规西医治疗措施的基础上加用参麦注射液。两组治疗1周后,比较临床症状、生命体征及实验室指标变化情况。结果观察组治疗总有效率显著高于对照组(P<0.05)。观察组肠内营养耐受率及中医症状改善率均显著高于对照组(P<0.05)。两组急性胰腺炎床旁评分及急性生理和慢性健康状况(APACHEⅡ)评分均较治疗前有所降低(P<0.05),观察组评分改善情况优于对照组(P<0.05)。两组血清白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)及白细胞介素-6(IL-6)水平均较治疗前有所降低(P<0.05),观察组治疗后各指标水平低于对照组(P<0.05)。另外,两组治疗过程中均未见严重不良反应。结论参麦注射液辅助治疗SAP能够改善患者临床症状,降低病情严重程度,改善临床预后。

Objective:To observe the clinical efficacy of Shenmai Injection in the adjuvant treatment of severe acute pancreatitis(SAP).Methods:SAP patients were randomly divided into a control group of 44 cases(2 cases dropped out,2 cases excluded,and finally 40 cases completed)and an observation group of 45 cases(1 case dropped out,3 cases excluded,and finally 41 cases completed)using a random number table method.The control group received routine medicine treatment,while the observation group received additional Shenmai Injection in addition to routine medicine treatment.After one week of treatment,the changes in clinical symptoms,vital signs,and laboratory indicators between the two groups were compared.Results:The total effective rate of the observation group was significantly higher than that of the control group(P<0.05).The tolerance rate of enteral nutrition and the improvement rate of traditional Chinese medicine symptoms in the observation group were significantly higher than those in the control group(P<0.05).The bedside score and APACHEⅡscore of two groups of patients with acute pancreatitis decreased compared with before treatment(P<0.05),and the observation group was better than the control group(P<0.05).The serum levels of WBC,CRP,PCT,and IL-6 in both groups of cases decreased compared to before treatment(P<0.05),and the observation group was better than the control group(P<0.05).In addition,no serious adverse reactions were observed during the treatment of both groups.Conclusion:Shenmai Injection as an adjuvant therapy for SAP can improve clinical symptoms,reduce the severity of the condition,and improve clinical prognosis.